NAMS Share Price Performance
US$27.87
2.87 (11.48%)
Price US$27.87
Share Pricen/a
Seeking Alpha • Jul 26
NewAmsterdam Pharma Company N.V. Stock Price
- 0 Narratives written by author
- 1 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
NAMS Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
No trending discussion available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
NewAmsterdam Pharma Company N.V. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -2.17
- 100.00%
- -3,644.21%
- 0%
About NAMS
- Founded
- n/a
- Employees
- 100
- CEO
- WebsiteView website
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
